Pharmacological rationale for antihypertensive drug choice on COVID-19-affected patients: ACEI/ARB might not increase their susceptibility.

Zhao, Hong-Jin; Yang, Xiao-Mei; Wang, Ai-Hong; Li, Yan

Zhao, Hong-Jin; Yang, Xiao-Mei; Wang, Ai-Hong; Li, Yan.

Zhao HJ; Department of Cardiology, Shandong Provincial Hospital affiliated to Shandong First Medical University, Ji'nan, China.
Yang XM; Department of Anesthesiology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Ji'nan, China.
Wang AH; Department of Cardiology, Shandong Provincial Hospital affiliated to Shandong First Medical University, Ji'nan, China.
Li Y; School of Medicine, Cheeloo College of Medicine, Shandong University, Ji'nan, China.

J Cell Mol Med ; 24(21): 12879-12881, 2020 11.

Article in English | MEDLINE | ID: covidwho-772416

Subject(s)

Angiotensin Receptor Antagonists/therapeutic use; Angiotensin-Converting Enzyme 2/metabolism; Angiotensin-Converting Enzyme Inhibitors/therapeutic use; Antihypertensive Agents/therapeutic use; COVID-19 Drug Treatment; Angiotensin Receptor Antagonists/pharmacology; Angiotensin-Converting Enzyme 2/genetics; Angiotensin-Converting Enzyme Inhibitors/pharmacology; Animals; Antihypertensive Agents/pharmacology; COVID-19/metabolism; Comorbidity; Female; Humans; Hypertension/drug therapy; Hypertension/epidemiology; Premenopause

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Angiotensin-Converting Enzyme Inhibitors / Angiotensin Receptor Antagonists / Angiotensin-Converting Enzyme 2 / COVID-19 Drug Treatment / Antihypertensive Agents Type of study: Observational study Limits: Animals / Female / Humans Language: English Journal: J Cell Mol Med Journal subject: Molecular Biology Year: 2020 Document Type: Article Affiliation country: Jcmm.15850

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google